Receptor binding

Receptor binding is the physical attachment of a drug molecule — called a ligand — to a receptor protein, typically embedded in a cell membrane. This contact is the first step by which most psychoactive substances initiate their effects in the brain and body.

Receptors are not passive docking sites. They are functional proteins that, when engaged in the right way, trigger a cascade of biochemical events inside the cell. Whether binding produces a response at all depends on the nature of the molecule — attachment and activation are separate events.

A key distinction in receptor pharmacology is between affinity — how strongly and reliably a molecule attaches — and efficacy — how strongly it activates the receptor once bound. A molecule can have high affinity while low efficacy, meaning it occupies the receptor without triggering its signal.

How it works · its role

Binding works through molecular complementarity: the shape, size, and charge distribution of the drug must fit a receptor's binding site closely enough to form a stable, transient complex. The lock-and-key analogy is common, though the fit is dynamic — both the ligand and the receptor can shift conformation on contact.

Molecules that bind and fully activate a receptor are called agonists. Those that bind without activating, blocking agonists in the process, are antagonists. A third class — partial agonists — activate the receptor, but only to a submaximal ceiling, regardless of how much drug is present.

Binding is temporary under normal conditions. The drug attaches, produces or suppresses a signal, then detaches. How long it remains bound — the dissociation rate — shapes the duration and sometimes the character of the effect. A small number of drugs bind so tightly they are effectively irreversible, persisting until the receptor protein is degraded and replaced.

Relevance to substances & effects

Nearly every class of psychoactive substance acts through receptor binding. Classic psychedelics such as LSD and psilocin bind as agonists at the 5-HT₂A serotonin receptor, driving the perceptual and cognitive changes that define a psychedelic experience. Opioids bind to mu, delta, and kappa opioid receptors — each subtype linked to different balances of pain suppression, euphoria, and sedation.

Cannabis acts through CB₁ and CB₂ cannabinoid receptors; benzodiazepines bind to the GABA-A receptor complex, amplifying inhibitory signalling and producing sedation and anxiety suppression. Dissociatives such as ketamine act primarily as antagonists at NMDA glutamate receptors.

Because most drugs engage more than one receptor type — and because a receptor family often contains subtypes with distinct effects — a substance's full effect profile reflects the combined weight of all its binding activity. This is why understanding receptor binding is foundational for reading the dose ranges, effect descriptions, and interaction data found elsewhere on this site.